共 41 条
- [1] Clinical outcome (CO) evaluation of very old (≥ 80 years) castration resistant prostate cancer (CRPC) patients (pts) treated with docetaxel (DOC): Preliminary results of an Italian multicenter retrospective study (DELPHI study).JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Maines, FrancescaBurgio, Salvatore LucaDi Lorenzo, GiuseppeScognamiglio, FlorindaZustovich, FableFacchini, GaetanoGamucci, TeresaProcopio, GiuseppeBortolus, RobertoLo Re, GiovanniLa Russa, FrancescaBonetti, AndreaMessina, CaterinaLodde, MichelePerin, AlessandraIacovelli, RobertoPappagallo, Giovanni L.Veccia, AntonelloCaffo, OrazioGalligioni, Enzo
- [2] Clinical outcomes (CO) and predictive factors (PRE) evaluation of young (<60 years) castration resistant prostate cancer (CRPC) patients, treated with docetaxel (DOC): Updated results of an Italian multicenter retrospective study (cooperative group for CYCLOP study)EUROPEAN JOURNAL OF CANCER, 2013, 49 : S705 - S705Caffo, O.Ortega, C.Di Lorenzo, G.La Russa, F.Burgio, L. S.Messina, C.Spizzo, G.Facchini, G.Pappagallo, G. L.Maines, F.
- [3] Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study).JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)Veccia, AntonelloBurgio, Salvatore LucaDi Lorenzo, GiuseppeOrtega, CinziaScognamiglio, FlorindaAieta, MicheleZustovich, FableMattioli, RodolfoMansueto, GiovanniFacchini, GaetanoProcopio, GiuseppeD'Angelo, AlessandroSpizzo, GilbertDonini, MaddalenaBortolus, RobertoVicario, GiovanniZucali, Paolo A.Basso, UmbertoLo Re, GiovanniCaffo, Orazio
- [4] Clinical outcomes of patients (pts) age 60 or younger treated with docetaxel (DOC) for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (CYCLOP study)JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)Veccia, AntonelloOrtega, Cinziadi Lorenzo, GiuseppeLa Russa, FrancescaBurgio, Salvatore LucaFacchini, GaetanoMessina, CaterinaSacco, CosimoSpizzo, GilbertAieta, MicheleLodde, MicheleMansueto, GiovanniZucali, Paolo A.D'Angelo, AlessandroIacovelli, RobertoMassari, FrancescoMorelli, FrancoProcopio, GiuseppeRuatta, FiorellaCaffo, Orazio
- [5] Clinical outcome (CO) and predictive factors (PRE) evaluation of young (≤60 years) castration-resistant prostate cancer (CRPC) patients, treated with docetaxel (DOC): Preliminary results of an Italian multicenter retrospective study (CYCLOP study).JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Caffo, OrazioOrtega, CinziaDi Lorenzo, GiuseppeLa Russa, FrancescaBurgio, Salvatore LucaMessina, CaterinaFacchini, GaetanoIacovelli, RobertoLodde, MicheleMorelli, FrancoMassari, FrancescoProcopio, GiuseppeZustovich, FableLo Re, GiovanniPegoraro, CristinaGamucci, TeresaPappagallo, Giovanni L.Veccia, AntonelloMaines, FrancescaGalligioni, Enzo
- [6] Impact of new agents (NAs) on post-docetaxel (DOC) survival of octogenarians with metastatic castration resistant prostate cancer (mCRPC) patients (pts): Results of an Italian multicenter retrospective study (DELPHI study).JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Veccia, AntonelloCaffo, OrazioBurgio, Salvatore Lucadi Lorenzo, GiuseppeOrtega, CinziaScognamiglio, FlorindaMattioli, RodolfoMansueto, GiovanniZustovich, FableAieta, MicheleFacchini, GaetanoProcopio, GiuseppeD'Angelo, AlessandroSpizzo, GilbertDe Giorgi, UgoDe Placido, SabinoRuatta, FiorellaGalligioni, Enzo
- [7] Safety and clinical outcome of a cohort of patients (pts) with castration resistant prostate cancer (CRPC) treated with abiraterone acetate (AA) in a named patient program (NPP): Updated results of a retrospective study from an Italian cooperative group.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)Caffo, OrazioFratino, LuciaLo Re, GiovanniBasso, UmbertoD'Angelo, AlessandroDonini, MaddalenaSantini, DanieleProcopio, GiuseppeMassari, FrancescoGasparro, DonatelloVerderame, FrancescoSacco, CosimoMessina, CaterinaIacovelli, RobertoZustovich, FableVicario, GiovanniFraccon, Anna PaolaConteduca, VincenzaMaines, FrancescaDe Giorgi, Ugo
- [8] Outcomes of elderly patients (pts) treated with docetaxel (DOC) for metastatic castration-sensitive prostate cancer (mCSPC): Results from ECHOS, a multicenter Italian observational study.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 153 - 153Caffo, OrazioMaruzzo, MarcoPravisano, FedericoButtigliero, ConsueloSoraru, MariellaMasini, CristinaGori, StefaniaSabbatini, RobertoPappalardo, AnnalisaCattrini, CarloFornarini, GiuseppeVittimberga, IsabellaRametta, AlessandroZucali, Paolo AndreaFantinel, EmanuelaGrillone, FrancescoFratino, LuciaGalli, LucaGiordano, MonicaBasso, Umberto
- [9] Clinical outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequences in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian studyANNALS OF ONCOLOGY, 2016, 27Caffo, O.Biasco, E.Facchini, G.Fratino, L.Gasparro, D.Mosillo, C.Maruzzo, M.Santini, D.Tucci, M.Ortega, C.Verderame, F.Scagliarini, S.Lo Re, G.Procopio, G.Fornarini, G.Campadelli, E.Sabbatini, R.Maines, F.De Giorgi, U.
- [10] Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian studyANNALS OF ONCOLOGY, 2016, 27Caffo, O.Biasco, E.Facchini, G.Fratino, L.Gasparro, D.Mosillo, C.Basso, U.Santini, D.Tucci, M.Ortega, C.Verderame, F.Scagliarini, S.Lo Re, G.Procopio, G.Fornarini, G.Campadelli, E.Sabbatini, R.Maines, F.De Giorgi, U.